Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 4:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Topical study cream Clear all
Completed Phase 1 Interventional

Topical Sodium Nitrite for Chronic Leg Ulcers in Adult Patients With Blood Disorders

NCT01316796
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell Disease, Chronic Hemolytic Disorders
Interventions
Sodium Nitrite Cream
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2018 · Synced Sep 22, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Results available

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)

NCT05032859
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
tapinarof cream, 1%, vehicle cream
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
2 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
57
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Sep 22, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Results available

Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis

NCT00617994
View directory record Official record
Conditions
Psoriasis
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Fridley, Minnesota • Rochester, New York • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 22, 2026, 4:52 PM EDT
Completed No phase listed Observational

Preferences & Treatment Satisfaction Drivers in Rosacea Patients

NCT02602470
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251), Azelaic Acid Cream, Metronidazole gel, Metronidazole cream, Metronidazole Emulsion, Metronidazole Lotion, Brimonidine Tartrate Gel
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 22, 2026, 4:52 PM EDT
Completed Phase 1 Interventional

Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection

NCT03239223
View directory record Official record
Conditions
HSIL, HSIL of Cervix, High-Grade Squamous Intraepithelial Lesions, High-grade Cervical Intraepithelial Neoplasia, Human Papilloma Virus, Cervical Cancer, Cervical Intraepithelial Neoplasia, Cervical Neoplasm, Cervical Dysplasia, CIN
Interventions
ABI-1968
Drug
Lead sponsor
Antiva Biosciences
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Los Angeles, California • Lake Worth, Florida • Idaho Falls, Idaho + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Sep 22, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis

NCT03107611
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus Cream, 1%, Placebo Cream
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
8 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
25
States / cities
Boynton Beach, Florida • Coral Gables, Florida • Miami, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced Sep 22, 2026, 4:52 PM EDT
Completed Phase 1 Interventional Results available

Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)

NCT02152007
View directory record Official record
Conditions
Pachyonychia Congenita
Interventions
1% sirolimus cream (TD201 1%)
Drug
Lead sponsor
TransDerm, Inc.
Industry
Eligibility
16 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Sep 22, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Results available

A Study of S6G5T-3 in the Treatment of Acne Vulgaris

NCT03761784
View directory record Official record
Conditions
Acne Vulgaris
Interventions
S6G5T-3, S6G5T-8
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
9 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Sep 22, 2026, 4:52 PM EDT
Not listed Phase 4 Interventional

Potential Effect of Topical Imiquimod on Atrial Ectopy in Patients With Actinic Keratosis

NCT01413763
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod cream 3.75%, Placebo cream
Drug
Lead sponsor
Medicis Global Service Corporation
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Fort Meyers, Florida
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Sep 22, 2026, 4:52 PM EDT
Completed Phase 4 Interventional

Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis

NCT00460083
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Elidel(R) (pimecrolimus 1%), EpiCeram(R) -ceramide based barrier repair cream
Drug · Device
Lead sponsor
Ceragenix Pharmaceuticals
Industry
Eligibility
2 Years to 12 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
San Diego, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 5, 2008 · Synced Sep 22, 2026, 4:52 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

NCT02078648
View directory record Official record
Conditions
Adult Brain Glioblastoma, Glioblastoma Multiforme
Interventions
SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose), Bevacizumab, SL-701 + GM-CSF, Imiquimod
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 22, 2026, 4:52 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Thermosensitivity of a Topical Palmitated Formulation of Capsaicin

NCT05649228
View directory record Official record
Conditions
Pain Management
Interventions
Capsaicin 0.1% Cream, Capsaicin Palmitate 0.25% Cream, Placebo Cream
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
35 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Sep 22, 2026, 4:52 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

NCT03903822
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-06700841, Vehicle (Placebo)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 22, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Results available

Open Label Safety Study of Xerese Cream in the Treatment of Recurrent Herpes Labialis in Children 6-11 Years Old

NCT01574612
View directory record Official record
Conditions
Herpes Labialis
Interventions
acyclovir/hydrocortisone cream
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
10
States / cities
Los Angeles, California • Opa-locka, Florida • West Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Sep 22, 2026, 4:52 PM EDT
Completed Phase 3 Interventional

S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Non-Ablative Facial Laser Resurfacing in Adults

NCT00110747
View directory record Official record
Conditions
Pain
Interventions
S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%), Placebo Peel
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
3
States / cities
Clinton Township, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Sep 22, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis

NCT02635204
View directory record Official record
Conditions
Psoriasis
Interventions
DFD06 Cream, Vehicle Cream
Drug
Lead sponsor
Promius Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
30
States / cities
Glendale, Arizona • Rogers, Arkansas • Fountain Valley, California + 26 more
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 22, 2026, 4:52 PM EDT
Active, not recruiting Phase 2 Interventional

Seal, Stopping Eczema and Allergy Study

NCT03742414
View directory record Official record
Conditions
Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
Interventions
Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care
Combination Product · Other
Lead sponsor
Kari Nadeau, MD, PhD
Other
Eligibility
1 Week to 12 Weeks
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Denver, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 22, 2026, 4:52 PM EDT
Completed Not applicable Interventional Results available

Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva

NCT00504023
View directory record Official record
Conditions
Vulvar Cancer
Interventions
imiquimod, biopsy, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
2
States / cities
New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 22, 2026, 4:52 PM EDT
Completed Phase 2 Interventional

Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis

NCT00021294
View directory record Official record
Conditions
Non-melanomatous Skin Cancer, Precancerous/Nonmalignant Condition
Interventions
eflornithine, triamcinolone
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Sep 22, 2026, 4:52 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of SST-6007, a Topical Sildenafil Cream, Compared to Placebo in Women With Female Sexual Arousal Disorder

NCT02570282
View directory record Official record
Conditions
Sexual Arousal Disorder
Interventions
Placebo, SST-6007
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
21 Years to 60 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Sep 22, 2026, 4:52 PM EDT
Recruiting Phase 2 Interventional

TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus

NCT06748404
View directory record Official record
Conditions
Immunotherapy-related Pruritus
Interventions
TriCalm Hydrogel®, Triamcinolone acetonide 0.1% cream
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 22, 2026, 4:52 PM EDT
Withdrawn Not applicable Interventional

The Study on Bacterial Load Following Open-to-air Management in Burn Patients.

NCT04502914
View directory record Official record
Conditions
Burns, Infection Wound, Bacterial Infections
Interventions
Open-to-air strategy, Traditional closed-wound management
Procedure
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Sep 22, 2026, 4:52 PM EDT
Completed Phase 3 Interventional Results available

A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

NCT03448939
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
S5G4T-1, S5G4T-2
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2021 · Synced Sep 22, 2026, 4:52 PM EDT
Completed Phase 2 Interventional

A Study of BRT-FC-83C for the Treatment of Atopic Dermatitis

NCT00883311
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
BRT-FC-83C
Device
Lead sponsor
Biomed Research & Technologies, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 30, 2010 · Synced Sep 22, 2026, 4:52 PM EDT